Secondline Chemotherapy Versus Best Supportive Care in Patient with Malignant Pleural Mesothelioma: A Retrospective Study

被引：5

作者：

Mutlu, Hasan ^{[1
]}

Buyukcelik, Abdullah ^{[5
]}

Karaca, Halit ^{[2
]}

Aksahin, Arzu ^{[3
]}

Berk, Veli ^{[2
]}

Aslan, Tuncay ^{[4
]}

Erden, Abdulsamet ^{[4
]}

Akca, Zeki ^{[6
]}

Ozkan, Metin ^{[2
]}

机构：

[1] Acibadem Kayseri Hosp, Dept Med Oncol, Kayseri, Turkey

[2] Erciyes Univ, Sch Med, Kayseri, Turkey

[3] Kayseri Res & Training Hosp, Dept Med Oncol, Kayseri, Turkey

[4] Kayseri Res & Training Hosp, Dept Internal Med, Kayseri, Turkey

[5] Acibadem Univ, Sch Med, Dept Internal Med, Istanbul, Turkey

[6] Mersin Govt Hosp, Dept Radiat Oncol, Mersin, Turkey

来源：

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION | 2013年 / 14卷 / 06期

关键词：

Mesothelioma; survival; secondline chemotherapy; best supportive care; PHASE-III TRIAL; EUROPEAN-ORGANIZATION; PROGNOSTIC-FACTORS; PEMETREXED PLUS; CISPLATIN;

D O I：

10.7314/APJCP.2013.14.6.3887

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Mesothelioma is a rare neoplasm arising from mesothelial surfaces with the malignant pleural mesothelioma (MPM) as the most common form. Secondline chemotherapy in MPM is still controversial and in this study we evaluated whether it is superior to best supportive care. Materials and Methods: A total of 51 patients with MPM from Acibadem Kayseri Hospital, Kayseri Training and Research Hospital and Erciyes University were analyzed retrospectively. The patients treated with secondline chemotherapies (SLCT) were compared with those treated with best supportive care (BSC) for overall survival. Results: The median overall survival (OS) for firstline chemotherapy -> SLCT and firstline chemotherapy -> BSC groups were 20.3 and 14.7 months respectively (p=0.079). After firstline chemotherapy the median OS for SLCT and BSC were 5.9 and 4.7 months (p=0.355). Discussion: Although there was a trend for improvement in overall survival in patients treated with secondline chemotherapy, the difference was not statistically significant. Our results do not support the proposal that secondline chemotherapy could be effective in patients with MPM.

引用

页码：3887 / 3889

页数：3

共 50 条

[41] Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma [J].

Kim, Roger Y. ;

Li, Yimei ;

Marmarelis, Melina E. ;

Vachani, Anil .

LUNG CANCER, 2021, 159 :107-110

[42] How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma? [J].

Sharkey, Annabel J. ;

O'Byrne, Kenneth J. ;

Nakas, Apostolos ;

Tenconi, Sara ;

Fennell, Dean A. ;

Waller, David A. .

LUNG CANCER, 2016, 100 :5-13

[43] Prophylactic radiotherapy in a single fraction of 10 Gy at intervention pleural site in patient with malignant pleural mesothelioma: A retrospective monocentric cohort study [J].

Carette, H. ;

Faivre, J. -C. ;

Salleron, J. ;

Baumann, A. -S. ;

Uwer, L. ;

Clement-Duchene, C. ;

Vignaud, J. -M. ;

Petit, I. ;

Siat, J. ;

Tiotiu, A. ;

Beckendorf, V. .

CANCER RADIOTHERAPIE, 2017, 21 (08) :774-783

[44] Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study) [J].

Raynaud, C. ;

Greillier, L. ;

Mazieres, J. ;

Monnet, I. ;

Mastroianni, B. ;

Robinet, G. ;

Fraboulet, G. ;

Dixmier, A. ;

Berard, H. ;

Lamy, R. ;

Letreut, J. ;

Lena, H. ;

Oliviero, G. ;

Botta, S. ;

Vergnenegre, A. ;

Borget, I. ;

Chouaid, C. .

BMC CANCER, 2015, 15

[45] The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma [J].

Shohdy, Kyrillus ;

Abdel-Rahman, Omar .

EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (06) :579-584

[46] Evaluation of quality of life in patients with advanced and metastatic breast cancer proposed for palliative chemotherapy and best supportive care versus best supportive care [J].

Ciuhu, Anda-Natalia T. ;

Nita, Gabriela I. Rahnea ;

Popescu, Mihaela T. ;

Nita, Roxana Andreea D. Rahnea .

CANCER RESEARCH, 2015, 75

[47] Chemotherapy Plus Best Supportive Care versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials [J].

Zhong, Chenxi ;

Liu, Hongcheng ;

Jiang, Liyan ;

Zhang, Wei ;

Yao, Feng .

PLOS ONE, 2013, 8 (03)

[48] Successful Salvage Chemotherapy with Gemcitabine and Vinorelbine in a Malignant Pleural Mesothelioma Patient Previously Treated with Pemetrexed [J].

Agatsuma, Toshihiko ;

Koizumi, Tomonobu ;

Yasuo, Masanori ;

Urushihata, Kazuhisa ;

Tsushima, Kenji ;

Yamamoto, Hiroshi ;

Hanaoka, Masayuki ;

Fukushima, Mana ;

Honda, Takayuki ;

Kubo, Keishi .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (12) :1180-1183

[49] Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting [J].

Arnpollini, Luca ;

Soltermann, Alex ;

Felley-Bosco, Emanuela ;

Lardinois, Didier ;

Arni, Stephan ;

Speck, Roberto F. ;

Weder, Walter ;

Opitz, Isabelle .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 35 (03) :457-462

[50] Survival Benefit of Multiagent Chemotherapy With and Without Curative Surgery for Malignant Pleural Mesothelioma [J].

Alnajar, A. ;

Rodriguez, E. ;

Razi, S. ;

Nguyen, D. ;

Villamizar, N. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) :S897-S898

← 1 2 3 4 5 →